You can buy Barinib at the lowest price at Nextgen.ooo online pharmacy. Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are protein tyrosine kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs are associated with autoimmune diseases such as rheumatoid arthritis. By inhibiting the action of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses.
 
Baricitinib was first approved by the European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults and was then approved by the FDA in 2018. The EC later approved baricitinib for the treatment of atopic dermatitis, making it the first JAK inhibitor used for this indication in Europe. While baricitinib was granted emergency use authorization in November 2020 for the treatment of COVID-19 in combination with remdesivir under an Emergency Use Authorization (EUA), the FDA fully approved baricitinib for the treatment of COVID-19 in May 2022.
 
In June 2022, the U.S. Food and Drug Administration (FDA) approved baricitinib for the treatment of severe alopecia areata (AA), an autoimmune disease that results in sudden and sometimes severe hair loss. Baricitinib is the first FDA-approved systemic drug for alopecia areata, meaning it treats the entire body rather than a specific area.